Presentation is loading. Please wait.

Presentation is loading. Please wait.

Felix Ratjen, Todd Durham, Tomas Navratil, Amy Schaberg, Frank J

Published byΘεοφιλά Γερμανός Modified over 5 years ago

Similar presentations

Presentation on theme: "Felix Ratjen, Todd Durham, Tomas Navratil, Amy Schaberg, Frank J"— Presentation transcript:

1 Long term effects of denufosol tetrasodium in patients with cystic fibrosis 
Felix Ratjen, Todd Durham, Tomas Navratil, Amy Schaberg, Frank J. Accurso, Claire Wainwright, Matthew Barnes, Richard B. Moss  Journal of Cystic Fibrosis  Volume 11, Issue 6, Pages (December 2012) DOI: /j.jcf Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

2 Fig. 1 Patient disposition. ITT = intent-to-treat; TID = three times daily. Journal of Cystic Fibrosis  , DOI: ( /j.jcf ) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

3 Fig. 2 Change from baseline in lung function by visit during the 48-week placebo-controlled period. Results are displayed for subjects with data at each time point. Values displayed are the adjusted means (and their standard errors) from an ANCOVA model with effects for pooled site and baseline value. CFB = change from baseline. (A) FEV1 (L); (B) FEV1 percent of predicted (%); (C) FEF25%–75% (L/s). Journal of Cystic Fibrosis  , DOI: ( /j.jcf ) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

4 Fig. 3 Forest plot of the treatment effect (and 95% CI) for the change from baseline FEV1 at Week 48 endpoint for prespecified subgroups. Values displayed are the treatment effects (differences in adjusted mean change from baseline) and their 95% confidence intervals, estimated from an ANCOVA model with effects for pooled site and baseline value. ITT = intent-to-treat. Journal of Cystic Fibrosis  , DOI: ( /j.jcf ) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

5 Fig. 4 Kaplan–Meier estimate of the time to first pulmonary exacerbation for three definitions of exacerbation. (A) Treatment with IV antibiotics for at least one respiratory sign or symptom. (B) Presence of at least 4 out of 12 signs and symptoms. (C) Investigator-defined event. Hazard ratios, their 95% confidence intervals, and P-values were obtained from a proportional hazards model with effects for treatment, pooled study site, and baseline FEV1. Journal of Cystic Fibrosis  , DOI: ( /j.jcf ) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Download ppt "Felix Ratjen, Todd Durham, Tomas Navratil, Amy Schaberg, Frank J"

Similar presentations

Efficacy and safety of Creon�� 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis  Bruce C. Trapnell, Karen Maguiness, Gavin.

Efficacy and safety of Creon�� 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis  Bruce C. Trapnell, Karen Maguiness, Gavin.
Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis  Michael W. Konstan, Felix Ratjen 

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis  Michael W. Konstan, Felix Ratjen 
IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis  Donald.

IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis  Donald.
Donald R. VanDevanter, David J. Pasta, Michael W. Konstan 

Donald R. VanDevanter, David J. Pasta, Michael W. Konstan 
Rapid emergence of a ceftazidime-resistant Burkholderia multivorans strain in a Cystic Fibrosis patient  Joshua R. Stokell, Raad Z. Gharaibeh, Todd R.

Rapid emergence of a ceftazidime-resistant Burkholderia multivorans strain in a Cystic Fibrosis patient  Joshua R. Stokell, Raad Z. Gharaibeh, Todd R.
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation.

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation.
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation  Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation  Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,
Use of high-dose ibuprofen in a pediatric cystic fibrosis center

Use of high-dose ibuprofen in a pediatric cystic fibrosis center
Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation.

Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation.
Felix Ratjen, Paul Koker, David E

Felix Ratjen, Paul Koker, David E
How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF?  Sarah P. Cohen, David M. Orenstein 

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF?  Sarah P. Cohen, David M. Orenstein 
H. Grasemann, E. Tullis, F. Ratjen  Journal of Cystic Fibrosis 

H. Grasemann, E. Tullis, F. Ratjen  Journal of Cystic Fibrosis 
A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children.

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children.
Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled.

Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled.
Measuring and improving respiratory outcomes in cystic fibrosis lung disease: Opportunities and challenges to therapy  Edith T. Zemanick, J. Kirk Harris,

Measuring and improving respiratory outcomes in cystic fibrosis lung disease: Opportunities and challenges to therapy  Edith T. Zemanick, J. Kirk Harris,
Patrick A. Flume, John P. Clancy, George Z. Retsch-Bogart, D

Patrick A. Flume, John P. Clancy, George Z. Retsch-Bogart, D
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation  Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation  Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,
Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint  D.R. VanDevanter, A. Yegin, W.J. Morgan,

Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint  D.R. VanDevanter, A. Yegin, W.J. Morgan,
Laura Viviani, Baroukh M. Assael, Eitan Kerem 

Laura Viviani, Baroukh M. Assael, Eitan Kerem 
Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection 

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection 

Similar presentations

Ads by Google